Neuroxt, Inc. appears in FDA device records as the applicant for a single 510(k) submission, K261805, received 1 June 2026 and decided 8 October 2026. The record identifies the device as NEXT-Cue, assigns product code QWT and regulation number 882.1454, and lists the review panel as Neurology. The company’s own published pages describe NEXT-Cue and two other named products, NEXT-SCN and NEXT-STAGE, for MRI-based analysis. The profile below separates what the FDA record establishes from what the manufacturer states about its products. [1][2][4][7]
The K261805 filing and its scope
FDA records show K261805 as a Traditional 510(k) with decision code SESE, meaning Substantially Equivalent, dated 8 October 2026. The submission was not reviewed by a third party, is not listed as a combination product, and has no authorized Predetermined Change Control Plan. A summary is indicated in the record. The applicant is Neuroxt, Inc., with a filing address in Seongdong-Gu, Seoul, Republic of Korea, and a correspondent contact named Sunyoung Kim. [1][2][3]
The openFDA entry gives the device name as NEXT-Cue and the device name in the openFDA block as prognostic assessment software of mild cognitive impairment, with device class 2, regulation number 882.1454, medical specialty Neurology, and product code QWT. An independent regulatory database record for the same submission repeats the applicant, product code, decision date, decision, submission type and Class 2 designation. [1][8]
Documented products
The manufacturer’s product pages describe NEXT-Cue as an AI-based solution that analyzes brain MRI together with clinical information to support the assessment of cognitive decline, intended to give clinicians additional insight in the care of patients at risk of Alzheimer’s disease. The same description appears on the company’s product index. [4][7]
Two further products are named on that index. NEXT-SCN is described as a multimodal platform that measures in-vivo synaptic integrity to objectively verify the impact of synapse-targeted therapies. NEXT-STAGE is described as inferring regional tau burden from routine MRI, positioned as PET-complementary and built for research teams in biopharma and academic hospitals. These descriptions are the manufacturer’s own; the numbered FDA sources cover NEXT-Cue only. [7][5]
Company statements and published materials
The company’s site describes NeuroXT as an AI company working on MRI-based brain imaging technology, with a stated vision of MRI-based AI solutions for neurodegenerative care. Its About page states that an AI model analyzes MRI scans to predict amyloid and tau burden. These are company-published claims, not findings from the FDA record. [5][6]
The company’s product information page lists no available eIFU or SBOM documents as of the page’s published state. Site footers name Seong Joon Kyung PhD and give a Seoul address matching the FDA filing address; the filing address is not treated here as a verified headquarters. No parent, brand or ownership relationship is established by the numbered sources. [9][4][5]
What the record does and does not show
The linked collection contains one 510(k) record, K261805, with one SESE decision; the sample of linked records is the same single entry. That count reflects the filings retrieved as of 20 November 2026 and is not a measure of total portfolio, sales or safety performance. No recall records appear in the retrieved sample. [1]
The sources do not establish commercial availability, customers, clinical performance, certifications or post-market history for any product. NEXT-SCN and NEXT-STAGE have no FDA submission in the numbered sources, and no clearance should be inferred for them. [7][1]

